​

Supernus Pharmaceuticals (SUPN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SUPN Stock Forecast

Supernus Pharmaceuticals (SUPN) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $64.00, with a high of $65.00 and a low of $63.00. This represents a 21.40% increase from the last price of $52.72.

$25 $33 $41 $49 $57 $65 High: $65 Avg: $64 Low: $63 Last Closed Price: $52.72

SUPN Stock Rating

Supernus Pharmaceuticals stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (64.29%), 5 Hold (35.71%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 5 9 Strong Sell Sell Hold Buy Strong Buy

SUPN Price Target Upside V Benchmarks

TypeNameUpside
StockSupernus Pharmaceuticals21.40%
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks18.71%

Price Target Trends

1M3M12M
# Anlaysts244
Avg Price Target$64.00$52.50$52.50
Last Closing Price$52.72$52.72$52.72
Upside/Downside21.40%-0.42%-0.42%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25-32--5
Sep, 25-32--5
Aug, 25-32--5
Jul, 25-23--5
Jun, 25-23--5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 08, 2025Piper Sandler$65.00$48.0035.42%23.29%
Sep 30, 2025Cantor Fitzgerald$63.00$47.4132.88%19.50%
Aug 29, 2025Piper Sandler$40.00$45.12-11.35%-24.13%
Jul 29, 2025Cantor Fitzgerald$42.00$33.4525.56%-20.33%
Sep 11, 2024David AmsellemPiper Sandler$36.00$33.497.49%-31.71%
May 24, 2024David AmsellemPiper Sandler$41.00$27.8547.22%-22.23%
Apr 08, 2024Irene BuhaloJefferies$40.00$32.2723.95%-24.13%
Apr 08, 2024Annabel SamimyStifel Nicolaus$38.00$32.2717.76%-27.92%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 23, 2025Cowen & Co.BuyBuyhold
Oct 09, 2025Piper SandlerNeutralOverweightupgrade
Sep 30, 2025Cantor FitzgeraldOverweightOverweighthold
Aug 29, 2025Piper SandlerNeutralNeutralhold
Oct 18, 2024Cowen & Co.BuyBuyhold
Oct 18, 2024Piper SandlerNeutralNeutralhold
Sep 10, 2024Piper SandlerOverweightNeutraldowngrade
May 24, 2024Cowen & Co.BuyBuyhold
May 24, 2024Piper SandlerOverweightOverweighthold
Apr 08, 2024JefferiesBuyBuyhold

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.41$1.01$1.13$0.02$1.34----
Avg Forecast$2.47$1.39$2.15$1.98$2.86$1.89$2.33$3.21$4.05
High Forecast$2.53$1.43$2.22$2.25$2.90$2.05$3.08$4.16$4.22
Low Forecast$2.40$1.36$2.12$1.79$2.83$1.73$1.58$2.25$3.98
Surprise %-2.43%-27.34%-47.44%-98.99%-53.15%----

Revenue Forecast

$500M $580M $660M $740M $820M $900M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$520.40M$579.77M$667.24M$607.52M$661.82M----
Avg Forecast$523.01M$579.80M$680.28M$598.26M$641.90M$619.17M$675.51M$756.83M$831.51M
High Forecast$532.98M$590.85M$696.05M$601.38M$645.53M$637.77M$697.83M$781.83M$858.99M
Low Forecast$512.65M$568.31M$672.85M$595.51M$639.54M$609.04M$666.34M$746.55M$820.22M
Surprise %-0.50%-0.00%-1.92%1.55%3.10%----

Net Income Forecast

$0 $50M $100M $150M $200M $250M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$126.95M$53.42M$60.71M$1.32M$73.86M----
Avg Forecast$79.12M$68.33M$75.16M$1.32M$158.84M$105.09M$129.52M$177.90M$224.80M
High Forecast$94.94M$81.99M$90.19M$1.58M$160.78M$113.99M$171.22M$230.71M$234.46M
Low Forecast$63.29M$54.66M$60.13M$1.05M$156.90M$96.20M$87.81M$125.09M$220.83M
Surprise %60.46%-21.81%-19.23%--53.50%----

SUPN Forecast FAQ

Is Supernus Pharmaceuticals stock a buy?

Supernus Pharmaceuticals stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Supernus Pharmaceuticals is a favorable investment for most analysts.

What is Supernus Pharmaceuticals's price target?

Supernus Pharmaceuticals's price target, set by 14 Wall Street analysts, averages $64 over the next 12 months. The price target range spans from $63 at the low end to $65 at the high end, suggesting a potential 21.40% change from the previous closing price of $52.72.

How does Supernus Pharmaceuticals stock forecast compare to its benchmarks?

Supernus Pharmaceuticals's stock forecast shows a 21.40% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the specialty & generic drug manufacturers stocks industry (18.71%).

What is the breakdown of analyst ratings for Supernus Pharmaceuticals over the past three months?

  • October 2025: 0% Strong Buy, 60.00% Buy, 40.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 0% Strong Buy, 60.00% Buy, 40.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 0% Strong Buy, 60.00% Buy, 40.00% Hold, 0% Sell, 0% Strong Sell.

What is Supernus Pharmaceuticals’s EPS forecast?

Supernus Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $1.89, marking a 41.04% increase from the reported $1.34 in 2024. Estimates for the following years are $2.33 in 2026, $3.21 in 2027, and $4.05 in 2028.

What is Supernus Pharmaceuticals’s revenue forecast?

Supernus Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $619.17M, reflecting a -6.44% decrease from the reported $661.82M in 2024. The forecast for 2026 is $675.51M, followed by $756.83M for 2027, and $831.52M for 2028.

What is Supernus Pharmaceuticals’s net income forecast?

Supernus Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $105.09M, representing an 42.28% increase from the reported $73.86M in 2024. Projections indicate $129.52M in 2026, $177.9M in 2027, and $224.8M in 2028.